Acute cyclosporine-induced nephrotoxicity in renal transplant recipients: The role of the transplanted kidney

Journal of the American Society of Nephrology

Volumn 7, Issue 12, 1996, Pages 2677-2681

  Wissmann, Charlotte ^a   Frey, Felix J ^a   Ferrari, Paolo ^a   Uehlinger, Dominik E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cyclosporine; Humans; Renal failure; Toxicity; Transplantation

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; PREDNISONE; URIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MECHANISM; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL; URIC ACID URINE LEVEL;

EID: 0030378087     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kahan BD, Oates JA, Wood AJJ: Cyclosporine. N Engl J Med 1989;321:1725-1738.
2. Remuzzi G, Bertani T: Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 1989;13:261-272.
3. Kopp JB, Klotmann PE: Cellular and molecular mechanisms of cyclosporine nephrotoxicity. J Am Soc Nephrol 1990;1:162-179.
4. Chapman JR, Griffiths D, Harding NG, Morris PJ: Reversibility of cyclosporin nephrotoxicity after three months' treatment. Lancet 1985;1:128-130.
5. Flechner SM, Van Buren C, Kerman RH, Kahan BD: The nephrotoxicity of cyclosporine in renal transplant recipients. Transplant Proc 1983;15[Suppl 1]:2689-2694.
6. Feutren G, Abeywickrama K, Friend D, Von Graffenried B: Renal function and blood pressure in psoriatic patients treated with cyclosporine A. Br J Dermatol 1990; 122[Supp 36]:57-69.
7. Barros EJG, Boim MA, Ajzen H, Ramos OL, Schor N: Glomeralar hemodynamics and hormonal participation on cyclosporine nephrotoxicity. Kidney Int 1987;32:19-25.
8. Murray BM, Paller MS, Ferris TF: Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 1985;28:767-774.
9. Bennett WM, Houghton DC, Buss WC: Cyclosporine-induced renal dysfunction: Correlations between cellular events and whole kidney function. J Am Soc Nephrol 1991;1:1212-1219.
10. McNally PG, Feehally J: Pathophysiology of cyclosporin A nephrotoxicity: Experimental and clinical observations. Nephrol Dial Transplant 1992;7:791-804.
11. Myers BD: Cyclosporine nephrotoxicity. Kidney Int 1986;30:964-974.
12. Curtis JJ, Dubovsky E, Whelchel JD, Luke RG, Diethelm AG, Jones P: Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 1986;2:477-479.
13. Higgins RM, Sheriff R, Bittar AA, et al.: The quality of function of renal allografts is associated with donor age. Transplant Int 1995;8:221-225.
14. Rao KV, Kasiske BL, Odlund MD, Ney AL, Andersen RC: Influence of cadaver donor age on posttransplant renal function and graft outcome. Transplantation 1990;49: 91-95.
15. Lucas BA, Vaughn WK, Spees EK, Sanfilippo F: Identification of donor factors predisposing to high discard rates of cadaver kidneys and increased graft loss within one year post transplantation. Transplantation 1987;43: 253-257.
16. The Canadian Multicenter Transplant Study Group: A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Lancet 1986;314:1219-1225.
17. Pappalettera M, Pizzi C, Cardillo M, et al.: Factors influencing cadaver kidney graft survival in two cyclosporine periods. Transplant Proc 1994;26:2533-2534.
18. Hall BM, Tiller DJ, Duggin GG, et al.: Post-transplant acute renal failure in cadaver renal recipients treated with cyclosporine. Kidney Int 1985;28:178-186.
19. Seron D, Carrera M, Grino JM, Castelao AM, Lopez-Costea MA, Riera L: Relationship between donor renal interstitial surface and posttransplant function. Nephrol Dial Transplant 1993;8:539-543.
20. Beutler D, Molteni S, Zeugin T, Thormann W: Evaluation of instrumental, nonisotopic immunoassays (fluorescence polarization imunoassay and enzyme-multiplied immunoassay technique) for cyclosporine monitoring in whole blood after kidney and liver transplantation. Ther Drug Monit 1992;14:424-432.
21. Frey FJ: Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients. Kidney Int 1991;39:1034-1050.
22. Tomlanovich S, Golbetz H, Perlroth M, Stinson E, Myers BD: Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephropathy. Am J Kidney Dis 1986;8:332-337.
23. Shemesh O, Golbetz H, Kriss JP, Myers BD: Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985;28:830-838.
24. Gupta AK, Rocher LL, Schmaltz SP, et al.: Short-term changes in renal function, blood pressure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders. Arch Intern Med 1991;151:356-362.
25. Laskow DA, Curtis JJ, Luke RG, et al.: Cyclosporine-induced changes in glomerular filtration rate and urea excretion. Am J Med 1990;88:497-502.
26. Scherrer U, Vissing SF, Morgan BJ, et al.: Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990;323:693-699.
27. Smith SR, Creech EA, Schaffer AV, et al.: Effects of thromboxane synthase inhibition with CGS 13080 in human cyclosporine nephrotoxicity. Kidney Int 1992;41: 199-205.
28. Pouteil-Noble C, Chapuis F, Berra N, et al.: Misoprostol in renal transplant recipients: A prospective, randomized, controlled study on the prevention of acute rejection episodes and cyclosporin A nephrotoxicity. Nephrol Dial Transplant 1994;9:552-555.
29. Van der Heide JJH, Bilo HJG, Donker JM, Wilmink JM, Tegzess AM: Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. N Engl J Med 1993;329:769-773.
30. Stanek B, Kovarik J, Rasoul-Rockenschaub S, Silberbauer K: Renin-angiotensin-aldosterone system and vasopressin in cyclosporine-treated renal allograft recipients. Clin Nephrol 1987;28:186-189.
31. Bantle JP, Boudreau RJ, Ferris TF: Suppression of plasma renin activity by cyclosporine. Am J Med 1987; 83:59-64.
32. Zidek W, Neumann KH: Calcium release in permeabilized neutrophils induced by cyclosporine. Nephron 1990;56:30-34.
33. Pfeilschifter J, Rüegg UT: Cyclosporine A augments angiotensin II-stimulated rise in intracellular free calcium in vascular smooth muscle cells. Biochem J 1987; 248:883-887.
34. Meyer-Lehnert H, Schrier RW: Cyclosporine A enhances vasopressin-induced calcium mobilization and contraction in mesangial cells. Kidney Int 1988;34:89-97.
35. Dawidson I, Rooth P: Improvement of cadaver renal transplantation outcomes with verapamil: A review. Am J Med 1991;90:37S-41S.
36. McNally PG, Walls J, Feehally J: The effect of nifedipine on renal function in normotensive cyclosporine-A-treated renal allograft recipients. Nephrol Dial Transplant 1990;5:962-968.
37. Wagner K, Albrecht S, Neumayer H-H: Prevention of posttransplant acute tubular necrosis by the calcium antagonist diltiazem: A prospective randomized study. Am J Nephrol 1987;7:287-291.
38. Adu D, Michael J, Turney J, McMaster P: Hyperkalaemia in cyclosporin-treated renal allograft recipients. Lancet 1983;2:370-371.
39. Mason J: Renal side-effects of cyclosporin A. Br J Dermatol 1990;122[Suppl 36]:71-77.
40. Bluhm RE, Rodgers WH, Black DL, Wilkinson GR, Branch R: Cholestasis in transplant patients - what is the role of cyclosporin? Aliment-Pharmacol-Ther 1992; 6:207-219.
41. Deray G, Benhmida M, Le Hoang P, et al.: Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med 1992;117:578-583.
42. Ruggenenti P, Perico N, Mosconi L, et al.: Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993;43:706-711.
43. Fuiano G, Sepe V, Cianfrone P, et al.: Acute effects of low-dose cyclosporine on renal function in normal subjects. Transplantation 1991;51:734-736.